Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-α antibodies

Clinical and Experimental Immunology

Volumn 154, Issue 3, 2008, Pages 325-331

  Ebert, E C ^a   Das, K M ^a   Mehta, V ^b   Rezac, C ^a  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b Mehta Bariatric Center   (United States)

Author keywords

Crohn's disease; Inflammatory bowel disease; Tumour necrosis factor; Ulcerative colitis

Indexed keywords

ANNEXIN; IMMUNOGLOBULIN G; INFLIXIMAB; NEUTRALIZING ANTIBODY; PROPIDIUM IODIDE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 2;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL SECRETION; CROHN DISEASE; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; APOPTOSIS; AUTOANTIBODIES; CELLS, CULTURED; ENZYME-LINKED IMMUNOSORBENT ASSAY; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOGLOBULIN G; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-2; MONOCYTES; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; TREATMENT FAILURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 55449085485     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2008.03773.x     Document Type: Article

References (28)

1. Allendoerfer R, Deepe GS. Blockade of endogenous TNFα exacerbates primary and secondary pulmonary histoplasmosis by differential mechanisms. J Immunol 1998 160 : 6072 82.
2. Kontoyiannis D, Pasparakis M, Pizarro TT, Cominelli F, Kollias G. Impaired on/off regulation of TNF biosynthesis in mice lacking TNF AU-rich elements: implications for joint and gut-associated immunopathologies. Immunity 1999 10 : 387 98.
3. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001 104 : 487 501.
4. Higuchi M, Aggarwal BB. TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J Immunol 1994 152 : 3550 8.
5. Tartaglia LA, Pennies D, Goeddel DV. Ligand passing: the 75 kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor. J Biol Chem 1993 268 : 18542 8.
6. Katarzyna Balcewicz-Sablinska M, Keane J, Kornfeld H, Remold HG. Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNFα. J Immunol 1998 161 : 2636 41.
7. Ten Hove T, van Montfrans C, Peppelenbosch MP, van Deventer SJH. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut 2002 50 : 206 11.
8. Lugering A, Schmidt M, Lugering N, Pauels H-G, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001 121 : 1145 57.
9. Mitoma H, Horiuchi T, Hatta N et al. Infliximab induces potent anti-inflammatory responses by outside-to-inside signals through transmembrane TNFα. Gastroenterology 2005 128 : 376 92.
10. Agnholt J, Dahlerup JF, Kaltoft K. The effect of etanercept and infliximab on the production of tumor necrosis factor α, interferon-γ and GM-CSF in in vivo activated intestinal T lymphocyte cultures. Cytokine 2003 23 : 76 85.
11. Cornillie F, Shealy D, D'Haens G et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001 15 : 463 73.
12. Agnholt J, Kaltoft K. Infliximab downregulates interferon-gamma production in activated gut T-lymphocytes from patients with Crohn's disease. Cytokine 2001 15 : 212 22.
13. Ringheanu M, Daum F, Markowitz J et al. Effects of infliximab on apoptosis and reverse signaling of monocytes from healthy individuals and patients with Crohn's disease. Inflamm Bowel Dis 2004 10 : 801 10.
14. Ohshima S, Saeki Y, Mima T et al. Long-term follow-up of the changes in circulating cytokines, soluble cytokine receptors, and white blood cell subset counts in patients with rheumatoid arthritis after monoclonal anti-TNFα antibody therapy. J Clin Immunol 1999 19 : 305 13.
15. Lorenz H-M, Antoni C, Valerius T et al. In vivo blockade of TNFα by intravenous infusion of a chimeric monoclonal TNFα antibody in patients with rheumatoid arthritis. J Immunol 1996 156 : 1646 53.
16. Charles P, Elliott MJ, Davis D et al. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNFα therapy in rheumatoid arthritis. J Immunol 1999 163 : 1521 8.
17. Gustot T, Lemmers A, Louis E et al. Profile of soluble cytokine receptors in Crohn's disease. Gut 2005 54 : 488 95.
18. Bendtzen K, Hansen MB, Ross C, Svenson M. High-avidity autoantibodies to cytokines. Immunol Today 1998 19 : 209 11.
19. Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol 1995 7 : 812 18.
20. Wadhwa M, Meager A, Dilger P et al. Neutralizing antibodies to granulocyte-macrophage colony-stimulating factor, interleukin-1α, and interferon-α but not other cytokines in human immunoglobulin preparations. Immunology 2000 99 : 113 23.
21. Ross C, Svenson M, Nielsen H, Lundsgaard C, Hansen MB, Bendtzen K. Increased in vivo antibody activity against interferon alpha, interleukin-1-alpha, and interleukin-6 after high-dose immunoglobulin therapy. Blood 1997 90 : 2376 80.
22. Sioud M, Dybwad A, Jespersen L, Suleyman S, Natvig JB, Forre O. Characterization of naturally occurring autoantibodies against tumour necrosis factor-alpha (TNF-α): in vitro function and precise epitope mapping by phage epitope library. Clin Exp Immunol 1994 98 : 520 5.
23. Mitoma H, Horiuchi T, Tsukamoto H. Binding activities of infliximab and etanercept to transmembrane tumor necrosis factor Gastroenterology 2004 126 : 934 5.
24. Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002 301 : 418 26.
25. Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum 2006 36 : 159 67.
26. Schmidt C, Giese T, Hermann E, Zeuzem S, Meuer SC, Stallmach A. Predictive value of mucosal TNFα transcripts in steroid-refractory Crohn's disease patients receiving intensive immunosuppressive therapy. Inflamm Bowel Dis 2007 13 : 65 70.
27. Louis E, Belaiche J, van Kemseke C et al. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn's disease. Eur J Gastroenterol Hepatol 1997 9 : 939 44.
28. Raddatz D, Bockemuhl M, Ramadori G. Quantitative measurement of cytokine mRNA in inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J Gastroenterol Hepatol 2005 17 : 547 57.